March 27th 2023
Representatives from Magellan Rx Management provided a detailed overview of current treatment options in ophthalmology and the impact that biosimilars could have.
Ranibizumab biosimilar achieves similar results in patients with polypoidal choroidal vasculopathy
September 27th 2022Anti-VEGF biosimilars may offer a therapeutic alternative to the original biologic because they have the ability to lower the overall therapeutic cost in the management of varied chorioretinal disorders.
Read More